NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Illuminare Biotechnologies

Illuminare Biotechnologies

Private
Brooklyn, New YorkHealthcare & Life Scienceshttps://illuminarebio.com/

Last Round

Seed Round

Jun 4, 2026

Total Funding Raised

$2.37M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Illuminare Biotechnologies is a biotechnology company that develops an intra-operative nerve visualization technology intended to reduce the risk of nerve damage.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Imaging, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

surgical imaging agentnerve visualizationfluorescence-guided surgeryiatrogenic nerve injurynerve sparing surgeryclinical-stage biotechsurgical dyeintraoperative imagingsmall-molecule fluorophorerobotic surgerymyelin bindingminimally invasive surgeryradical prostatectomythyroidectomy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Illuminare Biotechnologies Comparables

Compare Illuminare Biotechnologies with similar companies based on industry and business-model similarity.

Illuminare Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Trace Biosciences
92%
Alume Biosciences
90%
Blaze Bioscience, Inc.
66%

Illuminare Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Seed RoundJun 4, 2026
Series AAug 18, 2017

Key People

Founding team and executive leadership

Greg Ambra

Chief Operating Officer

Executive Team

Illuminare Biotechnologies Investors

Notable investors and investment history

Illuminare Biotechnologies investors
InvestorRounds
Thylacine CapitalSeed Round, Convertible Debt
Band of AngelsSeed Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 4, 2026

    Raised $3.65M in a seed funding round.

  • Apr 18, 2026

    Monthly visitors increased 52% MoM, reaching 1K.

Illuminare Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Illuminare Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Illuminare Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrooklyn, New York
Employee Range5
Year Founded2016
Last FundingJun 4, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.